Abstract | PURPOSE: METHODS: Eligible patients had MBC and received one prior chemotherapy regimen for metastatic disease; Performance status (PS) 0-2; measurable disease (RECIST criteria). PEM(500 mg/m2) was administered intravenously (IV) over 10 min prior to GEM(1,500 mg/m2) IV given over 30 min on day 1 every 14 days. RESULTS: Median age of the 16 patients in the study was 54 years (range 33-77). Fourteen patients had a PS of 0/1 and were evaluable for response. There were no reported complete or partial responses, seven patients with stable disease, six patients with disease progression and one patient with unknown response. Most common toxicities were skin rash: Grade 1/2(8) and Grade 3/4(1). Grade 3/4 non-hematological toxicities were fatigue(1); anorexia(1); pneumonia(1); peripheral ischemia(1) and elevation of liver transaminases(1). Three patients experienced febrile neutropenia (FN). This study did not meet the predefined criteria to proceed with additional accrual. CONCLUSIONS: This regimen of PEM and GEM showed no clinical activity in the dose and schedule tested.
|
Authors | Susan F Dent, Stan Gertler, Shailendra Verma, Roanne Segal, Vince Young, Rakesh Goel, Oliver Keller, Christina Canil, Neill Iscoe |
Journal | Cancer chemotherapy and pharmacology
(Cancer Chemother Pharmacol)
Vol. 65
Issue 3
Pg. 557-61
(Feb 2010)
ISSN: 1432-0843 [Electronic] Germany |
PMID | 19593565
(Publication Type: Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Glutamates
- Pemetrexed
- Deoxycytidine
- Guanine
- Gemcitabine
|
Topics |
- Adult
- Aged
- Anorexia
(chemically induced)
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Breast Neoplasms
(drug therapy, pathology)
- Deoxycytidine
(administration & dosage, adverse effects, analogs & derivatives)
- Drug Administration Schedule
- Exanthema
(chemically induced)
- Fatigue
(chemically induced)
- Female
- Glutamates
(administration & dosage, adverse effects)
- Guanine
(administration & dosage, adverse effects, analogs & derivatives)
- Humans
- Middle Aged
- Neoplasm Metastasis
- Pemetrexed
- Pneumonia
(chemically induced)
- Treatment Outcome
- Gemcitabine
|